Literature DB >> 3281821

Sulconazole. A review of its antimicrobial activity and therapeutic use in superficial dermatomycoses.

P Benfield1, S P Clissold.   

Abstract

Sulconazole is a substituted imidazole antimicrobial agent structurally related to other drugs in this group. It possesses a broad spectrum of activity in vitro against dermatophytes, yeasts and some Gram-positive bacteria. The efficacy and safety of sulconazole 1% cream has been demonstrated in controlled clinical studies in patients with superficial dermatophyte or yeast infections. In these trials, sulconazole generally displayed similar efficacy to clotrimazole, econazole and miconazole, although in a few studies sulconazole produced better and/or quicker improvement than clotrimazole or miconazole in small numbers of patients with tinea pedis. Further studies in larger groups of patients are needed to confirm these encouraging preliminary findings. Thus, sulconazole is an effective and well tolerated alternative to other topical imidazole drugs in the treatment of superficial fungal infections of the skin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3281821     DOI: 10.2165/00003495-198835020-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  18 in total

1.  Miconazole: a review of its antifungal activity and therapeutic efficacy.

Authors:  P R Sawyer; R N Brogden; R M Pinder; T M Speight; G S Avery
Journal:  Drugs       Date:  1975       Impact factor: 9.546

Review 2.  Clotrimazole: a review of its antifungal activity and therapeutic efficacy.

Authors:  P R Sawyer; R N Brogden; R M Pinder; T M Speight
Journal:  Drugs       Date:  1975       Impact factor: 9.546

3.  A double-blind parallel study of sulconazole nitrate 1% cream compared with miconazole nitrate 2% cream in dermatophytoses.

Authors:  L Gip; S Forsström
Journal:  Mykosen       Date:  1983-05

4.  Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importance.

Authors:  F C Odds
Journal:  J Antimicrob Chemother       Date:  1980-11       Impact factor: 5.790

5.  Relative inhibition factors--a novel approach to the assessment of antifungal antibiotics in vitro.

Authors:  F C Odds; A B Abbott
Journal:  J Antimicrob Chemother       Date:  1984-01       Impact factor: 5.790

6.  Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents.

Authors:  F C Odds; C E Webster; A B Abbott
Journal:  J Antimicrob Chemother       Date:  1984-08       Impact factor: 5.790

Review 7.  Tioconazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses.

Authors:  S P Clissold; R C Heel
Journal:  Drugs       Date:  1986-01       Impact factor: 9.546

8.  1% sulconazole cream v 2% miconazole cream in the treatment of tinea versicolor. A double-blind, multicenter study.

Authors:  L Tanenbaum; C Anderson; M J Rosenberg; W Akers
Journal:  Arch Dermatol       Date:  1984-02

9.  Effect of free fatty acids on liposome susceptibility to imidazole antifungals.

Authors:  I J Sud; D L Chou; D S Feingold
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

10.  A double-blind comparison of sulconazole nitrate 1% cream with clotrimazole 1% cream in the treatment of dermatophytoses.

Authors:  A Lassus; S Forström; O Salo
Journal:  Br J Dermatol       Date:  1983-02       Impact factor: 9.302

View more
  4 in total

1.  Use of caryophyllene oxide as an antifungal agent in an in vitro experimental model of onychomycosis.

Authors:  D Yang; L Michel; J P Chaumont; J Millet-Clerc
Journal:  Mycopathologia       Date:  1999-11       Impact factor: 2.574

Review 2.  Therapy of Skin, Hair and Nail Fungal Infections.

Authors:  Roderick Hay
Journal:  J Fungi (Basel)       Date:  2018-08-20

3.  Disruption of the NF-κB/IL-8 Signaling Axis by Sulconazole Inhibits Human Breast Cancer Stem Cell Formation.

Authors:  Hack Sun Choi; Ji-Hyang Kim; Su-Lim Kim; Dong-Sun Lee
Journal:  Cells       Date:  2019-08-30       Impact factor: 6.600

Review 4.  Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox.

Authors:  Aidan Kane; Dee A Carter
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.